Bristol Myers Squibb Co.
A new class of drugs are selective progesterone receptor modulators
Published in Cancer Law Weekly, June 19th, 2004
According to recent research published in the journal Steroids, "The identification of a new series of selective nonsteroidal progesterone receptor (PR) agonists is reported. Using a high-throughput screening assay based on the measurement of transactivation of a mouse mammary tumor virus promoter-driven luciferase reporter (MMTV-Luc) in human breast cancer T47D cells, a benzimidazole-2-thione analog was identified.
"Compound 1 showed an apparent EC50 of 53 nM and efficacy of 93% with respect to progesterone. It binds to PR with high affinity (K-i = 89 nM), but...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
Source: Cancer Law Weekly (2004-06-19)
More Articles from Cancer Law Weekly
- Accelerate Brain Cancer Cure
Alliance to boost research funding at St. Jude Children's Research Hospital - Medical Misconduct
Police say nurse arrested on child porn was 'predator' who worked in a daycare - Peregrine Pharmaceuticals
Patent granted for vasopermeation enhancement technology - Policlinic Umberto 1
A new assay quickly screens families at risk for medullary thyroid cancer - Silicon Graphics, Inc.
Altix system helps cancer center accelerate computational disease research
Japan Tobacco's strategies regarding evidence of tobacco health harms- More from this issue of Cancer Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
